A Big Pharma giant is deepening its investments in China, just as President Donald Trump has been pressuring the drugmaking industry to invest more heavily in US research and manufacturing, and pull back from operations in the world’s largest communist country.
In a statement posted on Eli Lilly & Co.’s Chinese website, Huzur Devletsah, senior vice president of the company and president and general manager of Lilly China, said Beijing remains a central pillar of the company’s long-term China strategy.
“Lilly remains committed to providing high-quality innovative medicines to Chinese patients and to actively participating in the development of the local innovation ecosystem,” Devletsah said. “Beijing is an important strategic market for Lilly in China, and Lilly’s goals in promoting the high-quality development of the biopharmaceutical industry are highly aligned with Beijing’s.”
The move also comes at a time of heightened geopolitical tensions between Washington and Beijing. Just days ago, President Trump announced a new sale of $11 billion in arms to Taiwan, which has been under threat from the mainland Communist regime.
Join the conversation as a VIP Member